Estrella Immunopharma (ESLA) risk factors

Item 1A of every Estrella Immunopharma, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open ESLA in Gloom →

Estrella Immunopharma's chart, financials and news, free in your browser.Open ESLA in Gloom →

FY2025 10-K risk factors
75 risks5 new10 dropped18 reworded
Estrella added risks regarding AI security, inflation, Nasdaq listing compliance, and clinical/licensing dependencies. The company dropped several risks related to its equity line purchase agreement with White Lion and warrant exercises.
Filed Mar 18, 2026
FY2024 10-K risk factors
80 risks
Estrella Immunopharma relies heavily on its Common Stock Purchase Agreement with White Lion, its ARTEMIS platform, and its partnership with Eureka for research and development.
Filed Sep 27, 2024